-
Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche
•
China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China to Rocephin, a long-acting, broad-spectrum cephalosporin antibiotic, from Swiss pharmaceutical giant Roche (SWX: ROG). This strategic move expands Hasten’s product offerings and strengthens its position in the Chinese market. Comprehensive Agreement Includes Marketing Authorization and…
-
Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results
•
China-based medical device firm Mindray (SHE: 300760) has released its financial reports for the year 2022 and the first quarter of 2023, showcasing robust growth across its main business units. In 2022, the company recorded a revenue of RMB 30.366 billion (USD 4.4 billion), marking a 20.17% increase year-on-year (YOY),…
-
Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement
•
The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications regarding the adjustment of the basic medical insurance (BMI) chronic disease drug lists for outpatients. These lists are significant as they often result in improved reimbursement conditions for patients and can lead to certain drugs…
-
Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE
•
The Center for Drug Evaluation (CDE) website indicates that China-based Huadong Medicine Co., Ltd (SHE: 000963) is on course to obtain breakthrough therapy designation (BTD) for its mefatinib. This second-generation irreversible EGFR/HER2 inhibitor is targeted for the treatment of first-line advanced non-small cell lung cancer (NSCLC) with rare mutations in…
-
VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion
•
China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round, securing an investment exceeding RMB 100 million. The funding round was led by V-Capital, Shengze Investment, Sunbow Capital, and VVB Fund. The capital raised will be strategically allocated to accelerate the company’s multiple clinical studies…
-
Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study
•
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received approval from the US Food and Drug Administration (FDA) to proceed with a Phase I clinical study for its drug 177Lu-LNC1003. This marks a significant milestone for the company as it advances its innovative treatment…
-
ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors
•
Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing in a Phase I clinical study for its investigational drug ABM-168 in the United States. This open, dosage escalation, dosage expansion study, which received approval in the country in October 2022, is designed to assess…
-
Kangrui Health Partners with West China Second University Hospital for Pediatric Care Innovation
•
Kangrui Health, a leading data and intelligence application company based in Beijing, has entered into a significant 10-year partnership with West China Second University Hospital. The collaboration focuses on the “Children’s Medical Counseling Game – Wonderful Hospital Series” technology translation project, which is set to revolutionize pediatric care approaches. West…
